Four in five Aussie asthma sufferers to breathe easier under new technology Tuesday, 29 April 2025 More than 2.2 million Australian people with asthma could benefit from life-changing digital inhaler technology which has the potential to save lives and ease the burden on Australia’s strained healthcare system. Approximately 2.8 million Australians have a diagnosis […]
$2.6 million capital raise to progress roll-out of Hailie® Smartinhaler® platform in the US 18 Mar 2025 | Image source: adherium.com Adherium is pleased to announce that it has received firm commitments to raise $2,600,000, before costs, through the issuance of approximately 2,600,000 convertible notes. Investors will also receive 1 attaching option for every 2 […]
Link Here Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce that it has commenced production and market release of the new, next generation Hailie® sensors with physiological parameters connecting GlaxoSmithKline (GSK) Ventolin®, Advair®/Flixotide® and Flovent®/Seretide® inhalers for monitoring Asthma […]
Melbourne, Australia; Link here – 27 July 2023: Adherium Limited (ASX: ADR), a leading provider of respiratory eHealth, remote monitoring and data management solutions, today announced it is entering a rapid commercialisation phase in reimbursed remote patient monitoring in the globally significant US market. Adherium’s leading position in remote patient monitoring, using the Hailie® app […]
Link here: Adherium Limited is pleased to announce that its UK value-add distribution partner, Helicon Health Ltd, has been awarded a prestigious 3 year Fellowship on the 2023 NHS Innovation Accelerator (NIA), to boost their new Director of Operations, Sander Ten Veldhuijs, in scaling the Hailie® Digital Inhaler solution across NHS England. The NIA programme […]
Adherium receives U.S. FDA 510(k) clearance for Teva’s ProAir® and Albuterol Sulphate inhaler users to remotely monitor physiological parametersMelbourne, Australia – 23 March 2023, Link Here : Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce that it has received U.S. Food and Drug […]
Melbourne, Australia – Link Here: Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce receiving Australian Therapeutic Goods Administration (TGA) approval to commercially distribute its new, next generation Hailie® sensors with physiological parameters. These latest additions to the Hailie sensor product family connect patients […]
Melbourne, Australia – 28 November 2022: (Link Here) Adherium Limited (“Adherium”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that is has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market application, connecting GlaxoSmithKline’s (GSK) Ventolin®, Advair®, and Flovent® pressurised metered dose inhaler (pMDI) users with […]
Melbourne, Australia – 20 September 2022 Link here : Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce a two-part clinical study at Washington University School of Medicine in St. Louis in the United States to monitor the adherence of Asthma patients using Adherium’s US […]
Melbourne, Australia Link Here – 16 September 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, has secured subscription commitments from the Company’s Chairman, new and existing institutional and sophisticated investors, including cornerstone investments from existing shareholders Trudell Medical and BioScience Managers Translation Fund […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: